- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
More ▼
Key statistics
On Wednesday, XOMA Corp (XOMAO:NMQ) closed at 24.95, -3.48% below its 52-week high of 25.85, set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.80 |
---|---|
High | 24.97 |
Low | 24.80 |
Bid | 24.54 |
Offer | 25.32 |
Previous close | 25.40 |
Average volume | 3.59k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 2.09 USD |
---|---|
Annual div yield (ADY) | 8.39% |
Div ex-date | Jul 03 2024 |
Div pay-date | Jul 15 2024 |
Data delayed at least 15 minutes, as of Jul 03 2024 17:21 BST.
More ▼